Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Erythromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (low certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo or vitamins (low certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Acyclovir probably leads to higher the proportion of participants with good or excellent rash… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Clarithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (moderate certainty).
1 finding from 1 review
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Flutamide 250 mg once to b.i.d. showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with spironolactone 100 mg (low certainty).
1 finding from 1 review
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review
Change in BMI ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found